Allografts News
-
CD Biosciences Announces Expanded Capabilities for Mechanistic Target of Rapamycin Research in Diabetes and Metabolism
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new services to study the Mechanistic Target of Rapamycin (mTOR) in diabetes and metabolism research. The mechanistic Target of Rapamycin is a serine/threonine protein kinase that is inhibited by rapamycin, a bacterial compound originally isolated from Easter Island soil that ...
-
OSSIO Receives Vizient Contract for Bio-Integrative Orthopedic Fixation Technology
OSSIO, Inc., an orthopedic fixation technology company, today announced that it has received a contract with Vizient, Inc., making the company’s portfolio of bio-integrative OSSIOfiber products available at negotiated pricing to health care providers in Vizient’s group purchasing organization (GPO) under a three-year contract starting March 1. OSSIO’s contract with Vizient ...
By OSSIO Inc
-
Isto Biologics Launches Influx™ Fibrant, a New Line of Advanced Allograft
Isto Biologics, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies, announced today the launch of Influx™ Fibrant, an unprecedented line of functional constructs derived from 100% cortical allograft. The cutting-edge line consisting of five new products includes Fibrant Anchor, Boat, Bullet, Pak and Wrap. The Fibrant launch features the patented ...
-
Cerapedics Announces FDA approval of an IDE supplement
Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for the on-going clinical trial, ASPIRE, for P-15L Bone Graft in a single level transforaminal lumbar interbody fusion (TLIF) surgery. “We are pleased to announce ...
-
Cerapedics Announces Results from Clinical Trial of i-FACTOR Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a ...
-
Axogen to Participate at Upcoming Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced it will participate in two investor conferences in February. Karen Zaderej, chairman, CEO, and president will participate in a fireside discussion at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on ...
-
Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter and full-year 2021 financial results on Tuesday, February 22, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. ...
-
Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2022 meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN), and the American Society for Reconstructive Microsurgery (ASRM). The meetings will be ...
-
Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Brown has been selected to ride on the 2022 Donate Life Rose Parade Float. Additionally, organ and tissue donor Paul Flanders will be honored through a floragraph that will adorn the ...
-
Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum. The presentation is scheduled for Thursday, November 18, 2021 at 10:00 a.m. ET. The ...
-
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO and president, will present at the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 17, 2021 at 4:25 p.m. (11:25 a.m. ET). The presentation will be webcast live and ...
-
TissueTech Grows Sales Force to Support Footprint Expansion
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, announced today that they had completed a new round of hiring for their two commercial subsidiaries Bio-Tissue and Amniox Medical. The recently hired sales representatives and associate sales ...
-
Bio-Tissue, Inc. Signs National Agreement with EyePro GPO to Afford Members Exclusive Treatment Options for Ocular Surface Disease and Disorders
Bio-Tissue, Inc., a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders, announced today that it has entered into a Vendor Agreement with EyePro Group Purchasing Organization (GPO), LLC. As such, GPO members can now take advantage of membership purchasing volume discounts to access ...
-
Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery
Cerapedics Inc., a private ortho-biologics company dedicated to enhancing the science of bone repair, announced today that results of a study to evaluate the cost-effectiveness of i-FACTOR Peptide Enhanced Bone Graft compared to autograft for patients undergoing ACDF surgery were recently published in ClinicoEconomics and Outcomes Research (July 2021, Volume 2021, Issue 13). In this landmark ...
-
SANUWAVE Rebrands to Reflect Evolved Wound Care Solutions
SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, today announced its rebranding. The new brand reflects the evolution of SANUWAVE’s solutions addressing the entire wound care pathway through its portfolio of noninvasive and ...
-
BioAesthetics Announces University Clinical Study for its Nipple Reconstruction Graft
BioAesthetics Corporation today announced a clinical study of its nipple reconstruction graft will be performed at Stanford Medicine beginning in 2021. The BioAesthetics® NACgraft™ biologic matrix is a decellularized skin allograft of the human nipple-areolar complex (NAC) intended to replace the NAC when lost due to mastectomy or other procedure. BioAesthetics hopes the NACgraft will ...
-
Cerapedics Announces Commercial Launch of i-FACTOR+ Matrix in Canada
Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. “We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, Chief Executive Officer of ...
-
SurGenTec® Announces First-of-its-Kind FDA Clearance for its 3D GraftRasp System™ Including Key Spine Indications
The 3D GraftRasp System is the only device to receive FDA clearance that allows for both decortication of bone and the delivery of autograft, allograft or synthetic bone graft. It is approved for general orthopedic use and spine procedures. “In spine procedures, the transverse processes and facet joints may now be targeted in a more efficient and effective surgical technique pioneered by ...
-
Cerapedics Announces Canadian Approval of its next-generation bone graft
Cerapedics, a private ortho-biologics company, today announced the Health Canada approval of the company’s next-generation bone graft called i-FACTOR+ Matrix, making it the first market to approve the commercial launch of this product. “We are excited to announce Canadian regulatory approval of our next-generation product, based on P15 osteogenic cell-binding peptide , i-FACTOR+ ...
-
Nanovis Expands the Range of Footprints for its Signature FortiCore Posterior Lumbar Interbody Fusion System
CARMEL, Ind., November 14, 2018— Nanovis, a leader in nanomedicine for the spine, today announced adding 22mm and 25mm lengths to its FortiCore® rotatable Posterior Lumbar Interbody Fusion (PLIF) devices. With over 5,000 FortiCore interbodies now implanted, Nanovis plans to further accelerate its technology driven growth with the expansion of their FortiCore PLIF product line with ...
By Nanovis
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you